Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.S&R Communications Group, a full-service healthcare marketing and communications company, has entered into a strategic partnership with Ovation Pharmaceuticals, a biopharmaceutical company, to launch Xenazine, a treatment for chorea associated with Huntington's disease.
Subscribe to our email newsletter
Xenazine is the first and only FDA-approved treatment specifically developed for any Huntington’s disease-related symptom, the company said.
Paul Dreyer, president of S&R, said: “In recent months, the S&R team worked tirelessly to help Ovation launch Xenazine. Having been involved since 2005 in marketing efforts for Xenazine, we know that it is a major advance for those with Huntington’s disease. We are pleased to help Ovation bring this important product to patients, physicians and caregivers.”